Introduction
Recent developments in treatment modalities for gastric cancer, on one hand, have allowed clinical oncologists a broad range of treatment options for patients with gastric cancer of various stages, and, at the same time, have caused some confusion and institutional differences in the selection of optimal treatment modalities. The Japanese Gastric Cancer Association (JGCA) issued the first version of their gastric cancer treatment guidelines (GLs) for doctors in March 2001, and those for patients in December 2001, with the aim of providing a reference for both clinical oncologists and patients how to select optimal treatments for various stages of disease. This article, which is a short summary of the Nishi Memorial Lecture given at the fourth International Gastric Cancer Association (IGCA) meeting in New York, in May, 2001, will serve to give a quick general view of JGCA gastric cancer treatment guidelines in response to the numerous inquiries from treatment modalities are also recommended to be investigated as clinical trials.
Target of GLs and how to use them
The JGCA provides GLs for all doctors and patients, who are going to make their treatment decisions on a common basis. GLs will facilitate the mutual understanding of treatment decisions between doctors and patients or their families. If doctors are planning to offer treatments different from those in the GLs, they are expected to explain the reasons for this difference to patients, and to when they obtain informed consent.
Revision of GLs
Treatment GLs should be always reviewed and revised associated with developments in the treatment of gastric cancer. A panel of the GL Development Committee of the JGCA is in charge of periodical review and revision, and discussion and proposals from members of the IGCA and JGCA are always welcome for this purpose.
Available treatment modalities for gastric cancer
The treatment modalities for gastric cancer available now in Japan are: endoscopic mucosal resection (EMR), laparoscopic gastrectomy, modified gastrectomy A and B (MG A and B), standard gastrectomy, extended gastrectomy, chemotherapy, radiotherapy, multimodality therapy (including neoadjuvant and adjuvant chemotherapy, immunochemotherapy, hyperthermochemotherapy), and terminal care.
Stage-oriented treatment indications
GLs show treatment indications according to the clinical stage (JGCA classification [1] ). The T category in the JGCA classification is identical to that in the TNM, but the N category is different from the TNM, and is based on the anatomical lymph node stations.
Treatments for stage IA (T1N0)
EMR or modified gastrectomy (MG) is indicated for this stage according to the following instructions (Table  1) .
EMR is indicated for patients with small mucosal cancer with no lymph node metastasis. Our database [2] suggests that intestinal-type mucosal cancer less than 2 cm in diameter has no lymph node metastasis. En-bloc resection is preferable because of the possible risk of residual cancer remaining after EMR, and 2 cm is the technical upper limit of en-bloc resection. Accurate assessment of the depth of wall invasion, histological type, and size of tumor is mandatory before the selection of EMR. Fragmented, or piece-meal resection is allowed as a clinical trial if planned so as to allow complete reconstruction of piecemeal specimens. Mucosal cancer that does not meet the above conditions should be treated by MG A.
As shown in Table 2 , modified gastrectomy (MG) is classified into MG A and B according to the extent of resection and lymph node dissection: gastrectomy of less than two-thirds of the stomach with dissection of D1 and no.7 (ϩ8a) lymph nodes is designated as MG A (see Table 2 footnote), and modified gastrectomy with dissection of D1 and no. 7, 8a and 9 lymph nodes is designated as MG B.
MG A is also indicated for differentiated submucosal cancer less than 1.5 cm in diameter. Submucosal cancer that does not meet this condition should be treated by MG B. The type of gastrectomy is shown in Table 2 .
Standard gastrectomy includes resection of more than two-thirds of proximal, distal, or total gastrectomy associated with D2 dissection according the size and location of the tumor. Regarding to the extent of D2 dissection, please refer to the General rule of gastric cancer study issued by the JGCA [1] . 
Treatments for stage IB (T1N1, T2N0)
As shown in Table 3 , MG B or standard gastrectomy is indicated for stage IB cancer according to the T and N categories. If a T1N1 tumor is less than 2.0 cm in diameter, MG B is indicated, and a T1N1 tumor larger than 2.1 cm or a T2N0 tumor is treated by standard gastrectomy.
Treatments for stage II (T1N2, T2N1, T3N0)
Standard gastrectomy is indicated for all categories of stage II cancer. Table 4 shows [3] [4] [5] , but to date, there is no single regimen that shows effectiveness for postoperative adjuvant chemotherapy [6] [7] [8] [9] [10] [11] [12] . Clinical trials should be conducted to establish standard regimens for adjuvant chemotherapy.
Treatments for stage IIIA (T2N2, T3N1, T4N0)
Standard or extended gastrectomy is indicated for stage IIIA cancer according to the T or N categories, as shown in the Table 5 .
Clinical trials of adjuvant and neoadjuvant chemotherapy are indicated for this stage. In T4 cancer, combined resection of involved organs is indicated, because the prognosis of patients with macroscopic residual tumor (R1 surgery) is obviously worse than that in those without residual tumor [2] .
Treatments for stage IIIB (T3N2, T4N1)
For stage IIIB, as for stage IIIA, standard or extended gastrectomy is indicated, according to the T and N categories (Table 6 ). Although the survival benefit of D3 for N2 cancer is not yet established, D3 is sometimes performed in Japan. A controlled randomized study comparing D2 and D3 was carried out in Japan, and its results may suggest new indications in this regard in the near future.
Combined resection of involved adjacent organ(s) is indicated for T4 cancer to achieve R0 resection. Adjuvant chemotherapy, neoadjuvant chemotherapy, and adjuvant radiotherapy should be performed in the setting of randomized controlled trials.
Treatments for stage IV (N3, CY1, M1)
Most cases of stage IV cancer cannot be curatively treated with surgery alone, except for those with N3 or T4N2 cancers. If N3 is the only determinant factor for stage IV, D3 surgery often achieves R0 resection.
There is no evidence of survival benefit of treatment modalities other than surgery for stage IV cancer, but some benefits are suggested for marginal lifeprolongation, tumor shrinkage, and relief of symptoms. Chemotherapy is indicated for patients with unresectable tumor with good performance status ( Table 7) . Standard regimens of chemotherapy for late-stage cancer are not yet established, although combination chemotherapy with cisplatin (CDDP), and 5-fluorouracil (5FU) or its derivatives may be the regimen of preference and recommendation [13] [14] [15] . When patients with fair or poor performance status are subjected to chemotherapy, they should be carefully treated by experienced chemotherapists, with the in- formed consent of the patients, otherwise they should not be treated with aggressive therapy, but with best supportive care [16] [17] [18] . Improvement in patients' QOL is the endpoint of therapy for this late-stage cancer.
Discussion
There are some issues to be kept in mind when these GLs are extrapolated to countries outside Japan, because treatment results may vary with various factors in regard to diagnosis, treatment, and patients' condition. GLs indicate treatments for diseases based on the clinical stages, but readers should be aware that the Japanese stage classification is different from those of the International Union Against Cancer (UICC)/AJCC system, mainly because of the difference in N categories. Careful reference to the Japanese classification [1] is necessary in this matter. The UICC/AJCC stage system cannot be used to plan treatment, because of its numeric system N staging.
There may be various arguments regarding the clinical significance of lymph node dissection, because all clinical trials in western countries [19] [20] [21] [22] were negative for a survival benefit of D2 node dissection. However, the survival benefit in these trials seems to be biased because of technical and patient factors; namely, the high incidence of postoperative complications and high operative mortality rates. Regardless of this high-level negative evidence for lymph node dissection, Japanese surgeons and some in western countries [23] still favor D2 dissection, and Oncology Practice GLs issued by the National Comprehensive Cancer Network in the United States [24] also recommend D2 dissection as their preference for resectable gastric cancer.
It is regretted that the GLs were not able to make any recommendations, as a daily practice, for standard chemotherapy regimens for advanced gastric cancer, although many favorable reports are available regarding the response rates of new anti-cancer drugs. However, these reports do not meet our conditions of recommendations for standard therapy, because the regimens show no or marginal survival benefit, with moderate or severe toxicity. Survival benefit for advanced gastric cancer may be achieved by multimodality therapy, i.e., by combinations of surgery, chemotherapy, and/or radiation therapy, in future trials. 
